PMID- 29548914
OWN - NLM
STAT- MEDLINE
DCOM- 20180926
LR  - 20180926
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 114
DP  - 2018 Jul 15
TI  - Attenuation of inflammation and cartilage degradation by sulfasalazine-containing 
      hyaluronic acid on osteoarthritis rat model.
PG  - 341-348
LID - S0141-8130(18)30176-4 [pii]
LID - 10.1016/j.ijbiomac.2018.03.059 [doi]
AB  - The aim of this study was to investigate the effects of a 
      sulfasalazine-containing hyaluronic acid (SASP/HA) systems on in vitro 
      anti-inflammation and the alleviation of cartilage degradation in both 
      lipopolysaccharide (LPS)-stimulated synoviocytes and a rat model of monosodium 
      iodoacetate (MIA)-induced osteoarthritis (OA). The SASP/HA resulted in long-term 
      release of SASP from the SASP/HA for up to 60 days in a sustained manner. In 
      vitro studies performed using real-time polymerase chain reaction (PCR) assay 
      revealed that the SASP/HA was able to effectively and dose-dependently inhibit 
      the mRNA expression levels of pro-inflammatory cytokines such as matrix 
      metalloproteinases-3 (MMP-3), cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), and 
      tumor necrosis factor-alpha (TNF-alpha) in LPS-stimulated synoviocytes. In vivo studies 
      showed that intra articular injection of SASP/HA greatly reduced the 
      MIA-stimulated mRNA expression of MMP-3, COX-2, IL-6, and TNF-alpha in blood. 
      Furthermore, these significant anti-inflammatory effects of SASP/HA contributed 
      markedly to the alleviation of progression of MIA-induced OA and cartilage 
      degradation, as demonstrated by X-ray, micro-computed tomography (micro-CT), 
      gross findings, and histological evaluations. Therefore, our findings indicated 
      that the long-term and sustained delivery of SASP using HA can play a therapeutic 
      role in alleviating inflammation as well as protecting against cartilage damage 
      in OA.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Kim, Sung Eun
AU  - Kim SE
AD  - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University 
      Guro Hospital, Korea University College of Medicine, #148, Guro-dong, Guro-gu, 
      Seoul 08308, Republic of Korea.
FAU - Lee, Jae Yong
AU  - Lee JY
AD  - Department of Biomedical Science, Korea University College of Medicine, Korea 
      University, Anam-dong, Seongbuk-gu, Seoul 02841, Republic of Korea.
FAU - Shim, Kyu-Sik
AU  - Shim KS
AD  - Department of Biomedical Science, Korea University College of Medicine, Korea 
      University, Anam-dong, Seongbuk-gu, Seoul 02841, Republic of Korea.
FAU - Lee, Sunghee
AU  - Lee S
AD  - BMI Korea R&D Center, Plant 11, Cheomdanro 7 Gil, Jeju City, Jeju-do 63309, 
      Republic of Korea.
FAU - Min, Kyoengwoo
AU  - Min K
AD  - BMI Korea R&D Center, Plant 11, Cheomdanro 7 Gil, Jeju City, Jeju-do 63309, 
      Republic of Korea.
FAU - Bae, Ji-Hoon
AU  - Bae JH
AD  - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University 
      Guro Hospital, Korea University College of Medicine, #148, Guro-dong, Guro-gu, 
      Seoul 08308, Republic of Korea.
FAU - Kim, Hak-Jun
AU  - Kim HJ
AD  - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University 
      Guro Hospital, Korea University College of Medicine, #148, Guro-dong, Guro-gu, 
      Seoul 08308, Republic of Korea.
FAU - Park, Kyeongsoon
AU  - Park K
AD  - Department of Systems Biotechnology, Chung-Ang University, Anseong, Gyeonggi-do 
      17546, Republic of Korea. Electronic address: kspark1223@cau.ac.kr.
FAU - Song, Hae-Ryong
AU  - Song HR
AD  - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University 
      Guro Hospital, Korea University College of Medicine, #148, Guro-dong, Guro-gu, 
      Seoul 08308, Republic of Korea. Electronic address: songhae@korea.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20180314
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Lipopolysaccharides)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - Animals
MH  - Cartilage/*metabolism/pathology
MH  - *Hyaluronic Acid/chemistry/pharmacology
MH  - Inflammation/chemically induced/drug therapy/metabolism/pathology
MH  - Lipopolysaccharides/toxicity
MH  - Osteoarthritis/chemically induced/*drug therapy/metabolism/pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Sulfasalazine/chemistry/pharmacology
OTO - NOTNLM
OT  - Hyaluronic acid
OT  - Osteoarthritis
OT  - Sulfasalazine
EDAT- 2018/03/20 06:00
MHDA- 2018/09/27 06:00
CRDT- 2018/03/18 06:00
PHST- 2018/01/11 00:00 [received]
PHST- 2018/03/05 00:00 [revised]
PHST- 2018/03/12 00:00 [accepted]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2018/09/27 06:00 [medline]
PHST- 2018/03/18 06:00 [entrez]
AID - S0141-8130(18)30176-4 [pii]
AID - 10.1016/j.ijbiomac.2018.03.059 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2018 Jul 15;114:341-348. doi: 
      10.1016/j.ijbiomac.2018.03.059. Epub 2018 Mar 14.